Evidence for the Inhibition of Dengue Virus Binding in the Presence of Silver Nanoparticles

Abstract

Dengue is an emerging hemorrhagic fever virus and widely considered the most important arbovirus in the world. Dengue virus (DENV) is a positive-sense RNA virus that exists in 4, potentially 5, antigenic serotypes. Currently, no vaccines or treatments are approved for DENV infections. Unsuccessful vaccine trials open the door for non-traditional treatments such as silver nanoparticles. Silver nanoparticles (AgNP) are known to inhibit viral replication of numerous viruses but have never before been tested for inhibition of dengue virus type 2 (DENV2, ATCC(registered trademark) VR-1584trademark). For the first time, this research presents up to a 96% reduction in DENV2 binding to Vero cells following pretreatment with AgNP (6-10nm, 25(mu)g/mL). These results suggest that similarly to other viruses, DENV2 can be inhibited at the first stage of the virus replication cycle, binding & entry.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 26, 2015
Accession Number
ADA614921

Entities

People

  • Kelley J. Williams

Organizations

  • Air Force Institute of Technology

Tags

DTIC Thesaurus Topics

  • Air Force
  • Antiviral Agents
  • Cell Physiological Processes
  • Cells
  • Civilian Personnel
  • Culture Techniques
  • Dengue
  • Epithelial Cells
  • Health Services
  • Infection
  • Medical Personnel
  • Rna Viruses
  • Statistical Analysis
  • United States
  • Viral Structures
  • Virus Diseases
  • Viruses

Fields of Study

  • Biology

Readers

  • Nanocomposite Materials Science
  • Virology (or Medical Virology).

Technology Areas

  • Biotechnology